Drug intelligence / Profile preview

CSD1903-12

Development stage: Preclinical
Lead developer: RAI Services
Modality: Small Molecules
Administration: Sublingual

Overview

CSD1903-12 is a soft nicotine lozenge developed by RAI Services Company. It is being investigated in a clinical study to assess its abuse liability, subjective effects, plasma nicotine uptake, and physiological measures. The product is available in 2 mg, 4 mg, and 8 mg nicotine strengths and is designed for ad libitum use.

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on CSD1903-12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CSD1903-12.

Explore the full profile